早期术后肝功能异常的风险因素和预测建模
Lin Zhong1, Hao-Yuan Wang1, Xiao-Na Li2
1Second Clinical Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China.
World journal of hepatology
|September 3, 2025
概括
在手术前肝酶升高,血小板数量低以及使用血红是术后肝功能障碍的关键危险因素. 一个新的模型有效地预测了各种手术中的肝损伤风险.
科学领域:
- 麻醉学和外科外科
- 肝病学
- 手术成果研究
背景情况:
- 对于影响非肝脏和非心脏手术后异常肝功能因素的研究有限.
- 了解这些因素对于改善患者的结果和制定有针对性的干预措施至关重要.
研究的目的:
- 在不同类型的手术中确定早期术后肝功能异常的危险因素.
- 开发和验证术后肝功能障碍的预测模型.
主要方法:
- 在5个外科部门对3720名患者进行了回顾性队列研究.
- 后勤回归和LASSO分析确定了风险因素,并构建了一个预测模型.
- 模型的性能是使用Hosmer-Lemeshow测试和ROC曲线分析进行的.
主要成果:
- 肝功能异常的关键预测因素包括手术前阿斯巴酸胺转移酶 (AST) 和氨酸转移酶 (ALT) 水平的升高,以及血小板数量的减少.
- 在手术期间使用赛沃也被认为是显著的危险因素.
- 开发的预测模型显示出强大的预测效率和良好的校准.
结论:
- 术前肝酶升高,血小板数量低,以及使用血红是术后肝损伤的重要危险因素.
- 已建立的风险预测模型在识别有肝功能障碍风险的患者方面表现出强大的有效性.
相关概念视频
Hepatic Drug Excretion: Influencing Factors
826
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
826
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
360
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
360
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
Drug Toxicity: Risk factors
248
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
248


